Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1546631 | 0.77 | EPHX2 (0.52) | MAPTGLAPOLBATMEPHX2 | |
| SCHEMBL15667389 | 0.76 | EPHX2 (0.50) | MAPTGLAPOLBATMEPHX2 | |
| SCHEMBL1738351 | 0.76 | CSNK2A2 (0.45) | MAPTGLAPOLBATMEPHX2 | |
| Hydrochloric Acid SCHEMBL30362216 | 0.74 | EPHX2 (0.49) | MAPTGLAPOLBATMEPHX2 | |
| SCHEMBL2553972 | 0.71 | EPHX2 (0.46) | MAPTGLAPOLBATMEPHX2 | |
| SCHEMBL1546077 | 0.71 | CDK1 (0.52) | MAPTGLAPOLBATMEPHX2 | |
| SCHEMBL16334263 | 0.71 | SMN1; SMN2 (0.66) | MAPTGLAPOLBATMEPHX2 | |
| SCHEMBL9412532 | 0.71 | KDM4E (0.51) | MAPTGLAATMEPHX2KMT2A | |
| SCHEMBL5433678 | 0.70 | MAPT (0.67) | MAPTGLAPOLBATMKMT2A | |
| SCHEMBL10178080 | 0.70 | CSNK2A2 (0.44) | MAPTGLAPOLBATMEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233863-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-RE49128-E1 | Hydroxyl purine compounds and applications thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-07-12 | — | — | US | disclosed |
| EP-3205652-B1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-10098885-B2 | Hydroxyl purine compounds and applications thereof | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-10-16 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-2951180-B1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2951180-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014120748-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-7098216-B2 | Thiazolopyrimidines useful as TNFα inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-29 | — | — | US | disclosed |
| US-6930101-B1 | Thiazolopyrimidines useful as TNFα inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-08-16 | — | — | US | disclosed |
| US-20050065116-A1 | Thiazolopyrimidines useful as TNFalpha inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-03-24 | — | — | US | disclosed |
| EP-1187838-B1 | Thiazolopyrimidines useful as TNF-Alpha inhibitors | UNIV CALIFORNIA (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-0611660-A2 | Condensed 5-membered heterocycles, process for their preparation and medicines containing these compounds | Dr. Karl Thomae GmbH (DE) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | PNP, PDE2A, PDE7A | MAPT 974/4885GLA 1003/4885POLB 343/4885 |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | MAPT 620/4885GLA 1092/4885POLB 419/4885 |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | MAPT 620/4885GLA 1092/4885POLB 419/4885 |
| US-20050065116-A1 | Thiazolopyrimidines useful as TNFalpha inhibitors | TNF, TNFRSF1A, TNFRSF9 | MAPT 3184/4885GLA 3870/4885POLB 2185/4885 |
| US-10098885-B2 | Hydroxyl purine compounds and applications thereof | PNP, PDE2A, PDE7A | MAPT 974/4885GLA 1003/4885POLB 343/4885 |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | DDX21, DPYD, NSUN2 | MAPT 3430/4885GLA 4199/4885POLB 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.